Details
 

August 4, 2020
12:00-1:00PM

XPOVIO® (selinexor) The first and only FDA-approved oral selective nuclear export inhibitor in relapsed refractory multiple myeloma (RRMM)

Hosted by Karyopharm

WEBINAR

Event Information

XPOVIO® Prescribing Information

Printer-Friendly Version


2020-08-04 2020-08-04 13:00:00 America/Detroit XPOVIO® (selinexor) The first and only FDA-approved oral selective nuclear export inhibitor in relapsed refractory multiple myeloma (RRMM) Event Information XPOVIO® Prescribing Information WEBINAR